E3 Ligase Ligand-Linker Conjugate

Thalidomide-4-NH-PEG1-NH2 TFA is an E3 ligase ligand-linker conjugate that targets Cereblon (CRBN). This compound serves as a critical ligand to recruit the CRBN protein, facilitating the development of proteolysis-targeting chimeras (PROTACs). It plays a significant role in studies focused on targeted protein degradation and E3 ligase modulation in biochemical and pharmacological research.

Thalidomide-O-C7-acid is a synthesized E3 ligase ligand-linker conjugate that utilizes the cereblon ligand derived from Thalidomide. This compound serves as a vital component in the development of PROTAC (proteolysis-targeting chimeras) technology, enabling targeted protein degradation. Thalidomide-O-C7-acid is instrumental for researchers focusing on protein regulation and therapeutic applications in various disease models.

Deoxy-thalidomide-Pip-C-PIP-boc is a conjugate that functions as an E3 ligase ligand-linker complex, featuring Thalidomide as a critical component. This compound acts as a Cereblon ligand, facilitating the recruitment of the CRBN protein, which is essential for targeted protein degradation. It serves as a vital intermediate in the synthesis of complete PROTAC (Proteolysis Targeting Chimeras) molecules, making it valuable for research in targeted therapeutic strategies and protein homeostasis.

Thalidomide-PIP-(R)C-pyrrolidine-boc is a conjugate that acts as an E3 ligase ligand-linker complex, incorporating Thalidomide as the enabling component. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein and serving as a crucial intermediate in the synthesis of PROTAC molecules. Its role in targeted protein degradation makes it a valuable tool for addressing complex biological questions in chemical biology and therapeutic development.

Thalidomide-NH-amido-C5-NH2 is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand, designed for applications in PROTAC (Proteolysis Targeting Chimeras) technology. This compound facilitates targeted protein degradation, enabling researchers to investigate proteostasis and elucidate cellular mechanisms. Its use in drug discovery can enhance the development of novel therapeutics by modulating protein levels and activity in complex biological systems.

Ethanolamine-Thalidomide-4-OH is an E3 ligase ligand-linker conjugate designed to facilitate targeted protein degradation via the proteolysis targeting chimera (PROTAC) approach. This compound combines a cereblon (CRBN) ligand with a linker, enabling the synthesis of various PROTACs, such as PROTAC BTK Degrader-13. It serves as a crucial tool for researchers investigating selective protein degradation mechanisms and developing novel therapeutic strategies.

E3 Ligase Ligand-linker Conjugate 214 is an innovative E3 ligase ligand-linker conjugate featuring a Von Hippel-Lindau (VHL) ligand. This compound effectively binds to target proteins, facilitating the formation of PROTAC (Proteolysis Targeting Chimeras) molecules, such as the PROTAC LSD1 Degrader 1. Its application in targeted protein degradation research supports the development of novel therapeutic strategies in cancer and other diseases.

(S,R,S)-AHPC-C5-COOH is an E3 ligase ligand-linker conjugate designed for the construction of PROTACs. It incorporates the VH032 VHL-based ligand, which is a selective and potent inhibitor of the VHL/HIF-1α interaction with a Kd of 185 nM. This compound is valuable for investigating models of anemia and ischemic diseases, providing a tool for targeted protein degradation research.

E3 Ligase Ligand-linker Conjugate 109 is an E3 ligase ligand-linker conjugate designed for the synthesis of PROTAC SOS1 degrader. This compound facilitates targeted protein degradation, enabling researchers to investigate the therapeutic potential of protein modulation in cellular systems. Its utility in developing targeted degradation strategies makes it an essential tool for drug discovery and development research.

E3 Ligase Ligand-linker Conjugate 108 is an E3 ligase ligand-linker conjugate designed for the synthesis of targeted protein degradation compounds. This reagent facilitates the development of PROTACs, specifically enabling the degradation of the SOS1 protein. It serves as a crucial tool in research applications focused on targeted protein modulation and therapeutic intervention in cellular processes related to disease states.

E3 Ligase Ligand-linker Conjugate 139 is designed to bind to E3 ubiquitin ligases, serving as a critical component in the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates ubiquitination and subsequent degradation of target proteins, making it a valuable tool for cancer research and therapeutic applications. Its unique properties enable efficient disruption of protein homeostasis, offering insights into cellular pathways and potential treatment strategies in oncology.

Thalidomide-NH-C4-Boc is a conjugate that targets the E3 ligase Cereblon through an innovative linker. This compound facilitates the synthesis of PROTAC CARM1/IKZF3 degrader-1, enabling targeted protein degradation studies. Its primary application lies in the development of novel therapeutics and novel molecular probes in cellular research.

6-Aminocaproic acid-(S,R,S)-AHPC-Me is a ligand and linker designed for E3 ubiquitin ligase in proteolysis-targeting chimeras (PROTACs). This compound plays a critical role in the development of targeted protein degradation approaches, making it valuable in tumor research and related applications. Its utilization in synthesizing PVD-06 highlights its importance in advancing therapeutic strategies against cancer.

DCAF11 ligand-Linker Conjugate 1 is a conjugate designed to facilitate targeted protein degradation through the DCAF11 E3 ubiquitin ligase. This compound serves as a key component for synthesizing PROTAC LGF308, enabling the selective degradation of specific proteins within cellular systems. Its utility in research applications includes the exploration of protein degradation pathways and investigating therapeutic targets in cancer and other diseases.